A Non-Randomized, Open-Label, One Treatment, One Group Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Patients With a Complicated Urinary Tract Infection
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
Price : $35 *
At a glance
- Drugs Nacubactam (Primary) ; Meropenem
- Indications Urinary tract infections
- Focus Pharmacokinetics
- Sponsors Roche
- 28 Feb 2018 Status changed from recruiting to completed.
- 24 Oct 2017 Planned End Date changed from 30 Dec 2017 to 12 Jan 2018.
- 24 Oct 2017 Planned primary completion date changed from 30 Dec 2017 to 12 Jan 2018.